Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
If you need an accessible version of this item, please submit a remediation request.
Date
2009-05-18
Language
American English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
BioMed Central
Abstract
Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?
Description
Keywords
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Schneider, B.P., Sledge, G.W. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?. Breast Cancer Res 11, 303 (2009). https://doi.org/10.1186/bcr2250
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Breast Cancer Research
Source
Publisher
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Final published version